LunarCrush LLM | creator/twitter::1310244506969583617/posts

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

[@m72068958](/creator/twitter/m72068958)
"$CRSP files patent for SyNTase (US 99421485) Evolving into a next-generation in vivo gene-editing platform company. With proof-of-concept data showing up to XX% editing efficiency SyNTase could redefine the future of gene therapy. Watch #CRSP. #CRISPR #SyNTase #GeneEditing"  
[X Link](https://x.com/m72068958/status/1974273962910925090) [@m72068958](/creator/x/m72068958) 2025-10-04T00:42Z XX followers, 1721 engagements


"1. Big moment for $CRSP. CRISPR Therapeutics just presented new preclinical data for CTX460 the first candidate from its SyNTase gene editing platform at #ESGCT2025. It targets Alpha-1 Antitrypsin Deficiency (AATD) a rare liver & lung disease with no curative options"  
[X Link](https://x.com/m72068958/status/1976619928737435660) [@m72068958](/creator/x/m72068958) 2025-10-10T12:04Z XX followers, XXX engagements

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@m72068958 "$CRSP files patent for SyNTase (US 99421485) Evolving into a next-generation in vivo gene-editing platform company. With proof-of-concept data showing up to XX% editing efficiency SyNTase could redefine the future of gene therapy. Watch #CRSP. #CRISPR #SyNTase #GeneEditing"
X Link @m72068958 2025-10-04T00:42Z XX followers, 1721 engagements

"1. Big moment for $CRSP. CRISPR Therapeutics just presented new preclinical data for CTX460 the first candidate from its SyNTase gene editing platform at #ESGCT2025. It targets Alpha-1 Antitrypsin Deficiency (AATD) a rare liver & lung disease with no curative options"
X Link @m72068958 2025-10-10T12:04Z XX followers, XXX engagements